Akari Therapeutics, Plc

NASDAQ: AKTX · Healthcare · Biotechnology

PublicHQ Tampa, FLCIK 0001541157Reports USD

#1 of 1,402 Healthcare companies by revenue

EA Score

——

FH 53DQ —GM —SS 43

v0.1 · 35/100 weight · pillars only

↑ balance-sheet leverage, listing tenure · ↓ workforce scale, return on equity

Methodology →

Revenue TTM

—

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$17.3M

Employees

Market cap

$15.3M

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Net income-$17.3M-$17.3M2025

Operating income-$17.3M-$17.3M2025

Total assets$47.9M$47.9M2025

Liabilities$19.6M$19.6M2025

Equity$28.3M$28.3M2025

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

Akari Therapeutics, Plc earned -$17.3M in FY2025 net income.

Peers · Healthcare

Conavi Medical Corp.——United Health Products, Inc.26D CalciMedica, Inc.——Anebulo Pharmaceuticals, Inc.——

Key facts

CEOAbizer Gaslightwala

SectorHealthcare

IndustryBiotechnology

HeadquartersTampa, FL

ExchangeNASDAQ: AKTX

Employees6

IPO date2014-01-06

Latest filings

No filings loaded.

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.